SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name **and** Ticker or Trading Symbol
Paulino Arleen (Last) (First) (Middle) ONE AMGEN CENTER DRIVE (Street) THOUSAND OAKS CA 91320 (City) (State) (Zip)	11/16/2026	AMGEN INC [AMGN] Foreign Trading Symbol

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)	5. If Amendment, Date of Original Filed (Month/Day/Year)
☐ Director ☐ 10% Owner ☑ Officer (give title below) ☐ Other (specify below) EVP, Operations	6. Individual or Joint/Group Filing (Check Applicable Line) ☑ Form filed by One Reporting Person ☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,455(1)(2)	D	
Common Stock	2,039.9774(3)	I	401(k) Plan

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Nqso (Right to Buy)	05/05/2022(4)	05/05/2030	Common Stock	5,314	236.36	D	
Nqso (Right to Buy)	04/30/2023(5)	04/30/2031	Common Stock	5,434	239.64	D	
Nqso (Right to Buy)	08/06/2023(6)	08/06/2031	Common Stock	40,595	230.15	D	
Nqso (Right to Buy)	05/02/2024(7)	05/02/2032	Common Stock	7,070	230.92	D	
Nqso (Right to Buy)	05/02/2025(8)	05/02/2033	Common Stock	7,166	235.97	D	
Nqso (Right to Buy)	05/07/2026(9)	05/07/2034	Common Stock	4,326	300.3	D	
Nqso (Right to Buy)	05/06/2026(10)	05/06/2035	Common Stock	6,214	270.44	D	
Nqso (Right to Buy)	05/05/2027(11)	05/05/2036	Common Stock	5,146	329.59	D	

Explanation of Responses:

1. These shares include 2,181 Restricted Stock Units (RSUs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan). Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

2. These shares include 66 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

3. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

4. 5,314 of these non-qualified stock options have vested and are exercisable.

5. 5,434 of these non-qualified stock options have vested and are exercisable.

6. 40,595 of these non-qualified stock options have vested and are exercisable.

7. 7,070 of these non-qualified stock options have vested and are exercisable.

8. 4,729 of these non-qualified stock options have vested and the remaining options will vest and become exercisable on 5/2/2027.

9. 1,427 of these non-qualified stock options have vested and the remaining options will vest and become exercisable in two annual installments, commencing on 5/7/2027.

10. 1,553 of these non-qualified stock options have vested and the remaining options will vest and become exercisable in three annual installments, commencing on 5/6/2027.

11. These non-qualified stock options will vest and become exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

Andrea A. Robinson, attorney-in-fact for Ms. Paulino	11/20/2026
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24

Power of Attorney

Know all men by these presents, that the undersigned hereby constitutes and appoints each of Andrea A. Robinson and Dennis Yai, signing singly, the undersigned's true and lawful attorney-in-fact to execute for and on behalf of the undersigned Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, as may be required as a result of the undersigned's position as an officer and/or director of Amgen Inc. (the "Company"), and to take any actions necessary or appropriate to enable the submission of such Forms to the Securities and Exchange Commission and to obtain, maintain or update EDGAR access for the undersigned, including preparing, executing and submitting a Form ID and related documents or information and acting as an account administrator for the undersigned?s EDGAR account (the ?related EDGAR actions?).

The undersigned hereby grants to each such attorney-in-fact full power and authority to execute such Forms 3, 4 and 5, or take any related EDGAR actions, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5, or take any related EDGAR actions, with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of November, 2026.

/s/ Arleen Paulino